Viridian Therapeutics target price raised to $40 from $22 by H.C. Wainwright
VRDN•H.C. Wainwright raised its target price for Viridian Therapeutics to $40 from $22.
Related News
HUYA caps awards under amended share incentive plan at 31,749,372 shares
HUYA•
Edwards Lifesciences target price raised to $112 from $101 by Leerink Partners
EW•
Walker & Dunlop posts Q3 loss on accelerated resolution of legacy loan repurchases
WD•
Bernstein raises McDonald's target price to $280 from $250
MCD•
Qualcomm: Barclays cuts target price to $150 from $180
QCOM•